Estratest
Result: $16.5 million settlement
Year: 2010
Yarrington v. Solvay Pharmaceuticals, Inc.
In March 2010, the Court granted final approval to a $16.5 million settlement of a false advertising class action lawsuit against Solvay Pharmaceuticals. Lieff Cabraser served as Co-Lead Counsel, representing purchasers of Estratest – a hormone replacement drug.
The complaint alleged that Solvay deceptively marketed Estratest as an FDA-approved drug when in fact Estratest was not approved by the FDA. The settlement provided refunds to consumers for up to 30% of the purchase price paid for Estratest. In addition, $8 million of the settlement was allocated to fund programs and activities related to women’s health concerns at medical schools throughout the nation.
Civil Litigation News
Final Approval Granted to $58 Million Settlement in Plaid Consumer Privacy Lawsuit
On July 20, 2022, U.S. District Judge Donna M. Ryu of the Northern District of California issued an order granting final approval to a
Judge Grants Preliminary Approval to $80M Volkswagen-Porsche Emissions Fraud Settlement
As reported by Law360, On June 29, 2022, U.S. District Judge Charles R. Breyer for the Northern District
Final Approval Granted to $38.5M National Grid Abusive Debt Collection Practices TCPA Settlement
On June 24, 2022, U.S. District Judge Joanna Seybert of the Eastern District of New York issued an order granting final approval
